Incyte Genomics Inc (INCY)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.18 (+0.26%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Incyte Genomics Inc (INCY)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Key Insights

Critical company metrics and information
  • Share Price

    $72.11
  • Market Cap

    $13.89 Billion
  • Total Outstanding Shares

    192.65 Million Shares
  • Total Employees

    2,524
  • Dividend

    No dividend
  • IPO Date

    November 3, 1993
  • SIC Description

    Services-commercial Physical & Biological Research
  • Homepage

    https://www.incyte.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$-2.04 Billion
Net Cash Flow$-1.92 Billion
Net Cash Flow From Operating Activities$101.85 Million
Net Cash Flow From Operating Activities, Continuing$101.85 Million
Net Cash Flow From Investing Activities, Continuing$24.48 Million
Exchange Gains/Losses$-7.84 Million
Net Cash Flow From Investing Activities$24.48 Million
Net Cash Flow, Continuing$-1.92 Billion
Net Cash Flow From Financing Activities$-2.04 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$273.86 Million
Costs And Expenses$4.13 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Income/Loss$-52.88 Million
Operating Expenses$3.84 Billion
Basic Average Shares$211.96 Million
Diluted Average Shares$211.94 Million
Revenues$4.08 Billion
Income Tax Expense/Benefit$241.38 Million
Net Income/Loss$32.48 Million
Selling, General, and Administrative Expenses$1.21 Billion
Gross Profit$3.78 Billion
Net Income/Loss Available To Common Stockholders, Basic$32.48 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$3.80 Billion
Net Income/Loss Attributable To Parent$32.48 Million
Cost Of Revenue$293.33 Million
Basic Earnings Per Share$0.10
Diluted Earnings Per Share$0.09
Research and Development$2.59 Billion
Income/Loss From Continuing Operations After Tax$32.48 Million
Other Operating Expenses$40.78 Million
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$1.84 Billion
Current Liabilities$1.50 Billion
Other Current Assets$2.74 Billion
Current Assets$2.81 Billion
Inventory$70.44 Million
Equity$3.17 Billion
Noncurrent Liabilities$339.56 Million
Liabilities And Equity$5.01 Billion
Assets$5.01 Billion
Wages$150.72 Million
Other Non-current Assets$1.43 Billion
Noncurrent Assets$2.20 Billion
Fixed Assets$773.10 Million
Equity Attributable To Parent$3.17 Billion
Other Current Liabilities$1.17 Billion
Accounts Payable$178.71 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.